GALE-301 Phase 2a clinical trial enrollment complete

Galena Biopharma (GALE) completes enrollment of the full 45-patient cohort for the Phase 2a clinical trial for GALE-301 (Folate Binding Protein (FBP) peptide immunotherapy). The two arms of the trial consist of HLA-A2-positive patients treated with the FBP peptide plus granulocyte macrophage-colony stimulating factor (GM-CSF) and an observational control group of HLA-A2-negative patients. After an initial induction series of six vaccinations given once per month, patients will receive booster inoculations at two subsequent six-month intervals. The primary objectives are to measure the immune response, time to recurrence and overall survival between treatment arms.

GALE-301 plus GM-CSF is an adjuvant treatment to prevent recurrences in high-risk ovarian and endometrial cancer patients rendered disease-free after completing standard-of-care therapy.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs